血液内科　ただいま診断中!

出版社： 中外医学社
著者：
発行日： 2017-04-15
分野： 臨床医学：内科  >  血液
ISBN： 9784498225046
電子書籍版： 2017-04-15 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

7,260 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,260 円(税込)

購入する
特記事項：

商品紹介

本書は血液内科を専門とはしないが，血液疾患を診る可能性のあるプライマリケア医，内科医，研修医などを対象に，血液疾患の基本的な知識と診断過程をわかりやすく解説することを目的にしている．まずは主訴や症候から始まる診断フローチャート的な目次で疾患の各論に導かれる．各論では診断に必要な基本的な知識や重要なポイントが提示され，その後で詳しい解説と会話形式で診断に至るまでの流れが理解しやすいように構成されている.

目次

  • 血液内科　ただいま診断中！

    ―目次―

    総論：「血液疾患を診る」ということ

    第1章：赤血球系（貧血を伴う疾患)
    第2章：白血球系疾患
    第3章：出血・凝固系疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 : 赤血球系 ( 貧血を伴う疾患 )

P.15 掲載の参考文献
1) 日本鉄バイオサイエンス学会治療指針作成委員会. 鉄剤の適正使用による貧血治療指針. 改訂第2版. 札幌 : 響文社 ; 2009.
 
2) Siegenberg D, et al. Ascorbic acid prevents the dose dependent inhibitory effect of polyphenols ad phytates on non-hem iron absorption. Am J Clin Nutr. 1991 ; 53 : 537-41.
 
3) 溝口秀昭, 他. 鉄欠乏性貧血に対するクエン酸第一鉄ナトリウムによる治療効果に及ぼす緑茶引用の影響. 診療と新薬. 1989 ; 26 : 1373-8.
 
P.33 掲載の参考文献
1) Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008 ; 112 : 2214-21.
 
2) Oberley MJ, Yang DT. Laboratory testing for cobalamin deficiency in megaloblastic anemia. Am J Hematol. 2013 ; 88 : 522-6.
PubMed
3) Charles S, et al. Drug induced Megaloblastic anemia. N Engl J Med. 2015 ; 373 : 1649-58.
 
4) Jaswal TS, et al. Serum lactate dehydrogenase in diagnosis of megaroblastic anemia. Indian J Pathol Microbiol. 2000 ; 43 : 325-9.
PubMed
5) Premkumar M, et al. Cobalamin and folic acid status in relation to the etiopathologenesis of pancytopenia in adults at a tertiary care centre in North India. Anemia 2012. doi : 10.1155/2012/707402
 
6) Fragasso A, et al. Functional vitamin B12 deficiency in alcoholics : An intriguing finding in a retrospective study of megaloblastic anemic patients. Eur J Int Med. 2010 ; 21 : 97-100.
 
7) Oosterhius WP, et al. Diagnostic value of the mean corpuscular volume in the detection of vitamin B12 deficiency. Scand J Clin Invest. 2000 ; 60 : 9-18
 
8) Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013 ; 368 : 149-60.
PubMed
9) Koike H, et al. The significance of folate deficiency in alcoholic and nutritional neuropathies : Analysis of a case. Nutrition. 2012 ; 28 : 821-4.
PubMed
P.42 掲載の参考文献
1) 特発性造血障害に関する調査研究. 赤芽球癆診療の参照ガイド 改訂第3版. http://zoketsushogaihan.com/file/guideline_H25/2.pdf
 
2) 廣川誠, 骨髄不全ガイドライン. 臨床血液. 2013 ; 54 : 1585-95.
 
3) Hirokawa M, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008 ; 93 : 27-33.
 
4) Hirokawa M, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy : a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015 ; 169 : 879-86.
 
5) Sawada K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2007 ; 92 : 1021-8.
 
6) Acquired pure red cell aplasia associated with malignant lymphomas : a nationwide cohort study in Japan for the PRCA collaborative study group. Am J Hematol. 2009 ; 84 : 144-8.
 
7) Lacy MQ, et al. Pure red cell aplasia : association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996 ; 87 : 3000-6.
PubMed
8) Go RS, et al. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 ; 98 : 483-5.
PubMed
9) 特発性造血障害に関する調査研究. 再生不良性貧血診療の参照ガイド 2014年改訂版. http://zoketsushogaihan.com/file/guideline_H25/1.pdf
 
10) Teramura M, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporine A with or without G-CSF in adult : a multicenter randomized study in Japan. Blood. 2007 ; 110 : 1756-61.
PubMed
11) 特発性造血障害に関する調査研究. 骨髄異形成症候群診療の参照ガイド 平成25年度改訂版. http://zoketsushogaihan.com/file/guideline_H25/3.pdf
 
12) Passweg JR, et al. Immunosuppressive therapy for patients with myelodysplastic sundrome : a prospective randomized multicenter Phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care. J Clin Oncol. 2011 ; 29 : 303-9.
 
13) Hata T, et al. Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. Int J Hematol. 2013 ; 98 : 687-93.
PubMed
14) Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 ; 89 : 2079-88.
PubMed
15) Greenberg P, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 ; 120 : 2454-65.
PubMed
P.81 掲載の参考文献
1) 特発性造血障害に関する調査研究. 自己免疫性溶血性貧血診療の参照ガイド 平成26年度改訂版.
 
2) Lechner K, et al. How I treat autoimmune hemolytic anemias in adults. Blood. 2010 ; 116 : 1831-8.
 
3) Berentsen S, et al. Primary chronic cold agglutinin disease : a population based clinical study of 86 patients. Haematologica. 2006 ; 91 : 460-6.
PubMed
4) 特発性造血障害に関する調査研究. 発作性夜間ヘモグロビン尿症診療の参照ガイド 平成26年改訂版. http://zoketsushogaihan.com/file/guideline_H25/4.pdf
 
5) Marchetti M, et al. Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis : analyzing the decision in different clinical scenarios. J Internal Med. 1998 ; 244 : 217-26.
PubMed
6) Yawata Y, et al. Characteristics features of the genotype and phenotype of hereditary spherocytosis in the Japanese population. Int J Hematol. 2000 ; 71 : 118-35.
PubMed
7) Boltom-Maggs PH, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2011 ; 156 : 37-49.
 
8) Buesing KL, et al. Partial splenectomy for hereditary spherocytosis : a multi-institutional review. J Pediatr Surg. 2011 ; 46 : 178-83.
PubMed
9) Ruiz EF, et al. Diagnostic approach to hemolytic anemias in the adult. Rev Bras Hemoter. 2015 ; 37 : 423-5.
PubMed
P.105 掲載の参考文献
1) 厚生労働省. 重篤副作用疾患別対応マニュアル. 薬剤性貧血. http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1f05.pdf
 
2) 厚生労働省. 重篤副作用疾患別対応マニュアル. 無顆粒球症. http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1f13.pdf
 
3) 厚生労働省. 重篤副作用疾患別対応マニュアル. 血小板減少症. http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1f17.pdf
 
4) George JN, et al. Drug-induced thrombocytopenia : pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009 : 153-8.
PubMed
5) Visentin GP, et al. Drug induced thrombocytopenia. Hematol Oncol Clin North Am. 2007 ; 21 : 685-96.
PubMed
6) Tesfa D, et al. Idiosyncratic dtug-induced agranulocytosis : Possible mechanism and management. Am J Hematol. 2009 ; 84 : 428-34.
 
7) Uetrcht J, et al. Idiosyncratic adverse drug reactions : current concepts. Phaemacol Rev. 2013 ; 65 : 779-808.
 
8) Warkentin TE, et al. Treatment and prevention of heparin-induced thrombocytopenia : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 : 340S-80S.
PubMed
9) De Angelis F, et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas : A retrospectivecohort study. Leuk Res. 2015 ; 39 : 1382-8.
 
10) Compagno N, et al. Immunogloblin replacement therapy in secondary hypogammagloblinemia. Front. Immunol. 2014 ; doi : 10.3389/fimmu.2014.00626
 
11) Department of Health Clinical Guideline Immunoglobline Use (2011, second edition)
 
12) Raanani P, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma : systematic review and meta-analysis. Leuk Lymphoma. 2009 ; 50 : 764-72.
PubMed

第2章 : 白血球系疾患

P.122 掲載の参考文献
1) Mrozek K, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 ; 30 : 4515-23.
PubMed
2) Bene MC, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood. 1998 ; 96 : 596-9.
 
3) 栗山一孝, 他. JALSGにおけるAMLの化学療法. スコアリングシステムを用いた予後判定. 臨床血液. 1998 ; 39 : 98-102.
 
4) Chiaretti S, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013 ; 98 : 1702-10.
PubMed
P.152 掲載の参考文献
1) Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood. 2013 ; 122 : 872-84. (ELN 2013 guideline)
 
2) Redaelli S, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012 ; 87 : E125-8.
PubMed
3) Kimura S, et al. BCR-ABL point mutations and TKI Treatment in CML patients. J Hematol Transfus. 2014 ; 2 : 1022.
 
P.163 掲載の参考文献
1) Halleck M. Chronic lymphocytic leukemia : 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013 ; 88 : 803-16.
 
2) Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 ; 371 : 213-23.
PubMed
3) Burger JA, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 ; 373 : 2425-37.
PubMed
4) Halleck M, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 ; 111 : 5446-56.
 
P.176 掲載の参考文献
1) Finazzi G, et al. Acute leukemia in polycythemia vera : an analysis of 1638 patients enrolled in prospective observational study. Blood. 2005 ; 105 : 2664-70.
PubMed
2) Tefferi A, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 ; 124 : 2507-13.
PubMed
3) Tefferi A. CME Information : Polycythemia vera and essential thrombocythemia : 2015 update on diagnosis, risk-staratification, and management. Am J Hematol. 2015 ; 90 : 162-73.
 
4) Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 ; 368 : 22-33.
PubMed
P.186 掲載の参考文献
1) Klampfi T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 ; 369 : 2379-90.
PubMed
2) Shirane S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015 ; 100 : e46-8.
PubMed
3) Passamonti F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012 ; 120 : 1197-201.
 
4) Wolanskyj AP, et al. Essential thrombocythemia beyond the first decade : life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006 ; 81 : 159-66.
PubMed
P.195 掲載の参考文献
1) Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 ; 113 : 2895-901.
 
2) Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis : a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 ; 115 : 1703-8.
 
3) Gangat N, et al. DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 ; 29 : 392-7.
 
P.203 掲載の参考文献
1) Parikh SA, Tefferi A. Chronic myelomonocytic leukemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012 : 87 : 611-9.
 
2) Such E, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013 ; 121 : 3005-15.
PubMed
3) Calvo X, et al. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML) : MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detaled review of prognostic factors in CMML. Leuk Res. 2015 ; 39 : 1146-53.
 
4) Wattel E, et al. A randomized trial of hydroxiurea versus VP-16 in adult chronic myelomonocytic leukemia. Blood. 1996 ; 88 : 2480-7.
 
P.211 掲載の参考文献
1) Hochberg J, et al. Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016 ; 173 : 637-50.
 
2) Laureny C, et al. Prevalence of common non-Hodgkin lymphomas and subtype of Hodgkin lemphoma by nodal site of involvement. A systematic review of 938 cases. Medicine. 2015 ; 94 : e987.
 
3) Sovani V, et al. Bone marrow trephine biopsy involvement by lymphoma : review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings, J Clin Pathol. 2014 ; 67 : 389-95.
PubMed
4) Vassilakopoulos TP, et al. Application of a prediction rule to select which patients presenting with lymphoadenopathy should undergo a lymph node biopsy. Medicine. 2000 ; 79 : 338-47.
 
5) Hochberg J, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma : state of the science. Br J Haematol. 2009 ; 144 : 24-40.
PubMed
6) Batata A, et al. Diagnostic value of clonality of surface immunoglobulin light and heavy chains in malignant lymphoproliferative disorders. Am J Hematology. 1993 ; 43 : 265.
 
7) Pastore A, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy forfollicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 ; 16 : 1111-22.
 
8) Salles G, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) : a phase 3, randomised controlled trial. Lancet. 2011 ; 377 : 42-51.
 
9) Trotman J, et al. Positron emission tomography-computed tomography (PETCT) after induction therapy is highly predictive of patient outcome in follicular lymphoma : analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011 ; 29 : 3194-200.
 
10) Thieblemont C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000 ; 95 : 802-6.
PubMed
11) Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the National LymphoCare Study. J Clin Oncol. 2015 ; 33 : 2516-22.
PubMed
12) Gribben JG. How I treat indolent lymphoma. Blood. 2007 ; 109 : 4617-26.
 
13) Ardeshna KM, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma : a randomised controlled trial. Lancet. 2003 ; 362 : 516-22.
PubMed
14) Solal-Celigny P, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas : final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998 ; 16 : 2332-8.
 
15) Zucca E, et al. Addition of rituximab to chlorambucil produces superior eventfree survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma : 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 ; 31 : 565-72.
 
16) Ardeshna KM, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma : an open-label randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 424-35.
PubMed
17) Morel P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 113 : 4163-70.
PubMed
18) Zhou Z, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 ; 123 : 837-42.
PubMed
19) Spaepan K, et al. Eaely restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol. 2002 ; 13 : 1356-63.
 
20) Zinzani PL, et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer. 2011 ; 117 : 1010-8.
PubMed
21) Yang DH, et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011 ; 43 : 1312-8.
 
22) Pregno P, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012 ; 119 : 2066-73.
PubMed
23) Adams HJ, et al. Prognostic value of complete remission status at end-oftreatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma : systematic review and meta-analysis. Br J Haematol. 2015 ; 170 : 185-91.
 
24) Vose JM. Mantle cell lymphoma : 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013 ; 88 : 1083-8.
 
25) Hoster E, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 ; 32 : 1338-46.
PubMed
26) Fernandez V, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010 ; 70 : 1408-18.
PubMed
27) Determann O, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy : results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008 ; 111 : 2385-7.
 
28) Sehn LN, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 ; 109 : 1857-61.
 
29) Thomas DA, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 ; 106 : 1569-80.
PubMed
30) Aukema SM, et al. Double-hit B-cell lymphomas. Blood. 2011 ; 117 : 2319-31.
PubMed
31) Johnson NA, et al. Concurrent expression of MYC and BCL2 in diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 ; 30 : 3452-9.
PubMed
32) Perry AM, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014 ; 165 : 382-91.
PubMed
33) Howlett C, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas : a systematic review and meta-analysis. Br J Haemetol. 2015 ; 170 : 504-14.
PubMed
34) Ship MA, et al. Case 12-2005 : a 30-year-old woman with a mediastinal mass. N Engl J Med. 2005 ; 352 : 1697-704.
 
35) Vose J, et al. International peripheral T-cell and natural killer/T-cell lymphoma study : pathology findings and clinical outcomes. J Clin Oncol. 2008 ; 26 : 4124-30.
PubMed
36) Leveal L, et al. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009 ; 148 : 673-89.
 
37) Ferreri AJ, et al. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013 ; 85 : 206-15.
PubMed
38) Ferreri AJ, et al. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012 ; 83 : 293-302.
PubMed
39) Savage KJ, et al. Peripheral T cell lymphoma-Not otherwise specified. Crit Rev Oncol Hematol. 2011 ; 79 : 321-9.
PubMed
40) Gallamini A, et al. Peripheral T-cell lymphoma unspecified (PTCL-U) : a new prognostic model from a retrospective multicentric clinical study. Blood. 2004 ; 103 : 2474-9.
 
41) Tokunaga T, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma : a multicenter cooperative study in Japan. Blood. 2012 ; 119 : 2837-43.
PubMed
42) Federico M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma : analysis of the International Peripheral T-Cell Lymphoma Project. J Clin Oncol. 2012 ; 31 : 240-6.
PubMed
43) Ishitsuka K, et al. Human T-cell leukemia virus type I and adult T-cell leukemia-lymphoma. Lancet Oncol. 2014 ; 15 : e517-26.
PubMed
44) Katsuya H, et al. Prognostic index for acute-and lymphoma- type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012 ; 30 : 1635-40.
PubMed
45) 「本邦におけるHTLV-1感染及び関連疾患の実態調査と総合対策」研究班. HTLV-1キャリア指導の手引き. 2011. http://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou19/dl/htlv-1_d.pdf
 
46) Suzuki R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000 ; 96 : 2993-3000.
PubMed
47) Moccia AA, et al. International prognostic score in advanded stage Hodgkin lymphoma : altered utility in the modern era. J Clin Oncol. 2012 ; 30 : 3383-8.
 
48) Hansenclever D, Diehl V. A prognostic score for advanced Hodgkin lymphoma. N Engl J Med. 1998 ; 339 : 1506-14.
 
49) Lynch RC, et al. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book. 2016 ; 35 : e376-85.
PubMed
50) Press OW, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging : Southwest Oncology Group S0816. J Clin Oncol. 2016 ; 34 ; 2020-7.
 
51) Schaapveld M, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015 ; 373 : 2499-511.
PubMed
52) Ganesan P, et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ann Oncol. 2015 ; 26 : 1170-4.
PubMed
53) Gallamini A, et al. Interim PET-adapted chemotheapy in advanced Hodgkin lymphoma (HL) : Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial. Paper presented at : 13th International Conference on Malignant Lymphoma ; June 2015 ; Lugano, Switzerland.
 
54) Lister TA, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol. 1989 ; 7 : 1630-6.
PubMed
P.248 掲載の参考文献
1) Levine J, et al. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010 ; 28 : 4831-41.
 
P.273 掲載の参考文献
1) 厚生労働省. HTLV-1キャリア指導の手引き. 2011. http://www.mhlw.go.jp/bunya/Kenkou/kekkaku-kansenshou19/dl/htlv-1_d.pdf
 
P.281 掲載の参考文献
1) Hyden A, et al. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphhistiocytosis : a systematic scoping review. Blood Rev. 2016 ; 30 : 411-20.
 
2) Romos-Casal M, et al. Adult haemophagocytic syndrome. Lancet. 2014 ; 383 : 1503-16.
 
3) Henter JI, et al. HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 ; 48 : 124-31.
PubMed
4) Filipovich AH, Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009 ; 127-31.
PubMed
5) Ishii E, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007 ; 86 : 58-65.
PubMed
P.289 掲載の参考文献
1) Palumbo A, et al. Multiple myeloma. N Engl J Med. 2011 ; 364 : 1046-60.
PubMed
2) 日本骨髄腫学会, 編. 多発性骨髄腫の診療指針. 第3版. 東京 : 文光堂 ; 2012.
 
3) Rajkumar SV. Update diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016 ; 35 : e418-23.
PubMed
4) Terpos E, et al. The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016 ; 35 : e407-17.
PubMed
5) 日本骨髄腫学会, 編. 多発性骨髄腫の診療指針. 第4版. 東京 : 文光堂 ; 2016.
 
6) Harada H, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993 ; 81 : 2658-63.
PubMed
7) Kawano MM, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993 ; 82 : 564-70.
PubMed
8) Manier S, et al. Future directions in the evaluation and treatment of precursor plasma cell disorders. Am Soc Clin Oncol Educ Book. 2016 ; 35 : e400-6.
PubMed
9) Rajkumar SV, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood. 2005 ; 106 : 812-7.
PubMed
10) Korde N, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) : novel biological insights and development of early treatment strategies. Blood. 2011 ; 117 : 5573-81.
PubMed
11) Dispenzieri A, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 ; 111 : 785-9.
PubMed
12) Durie BGM, et al. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 ; 36 : 842-54.
 
13) Greipp RP, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 ; 23 : 3412-20.
 
14) Palumbo A, et al. Revised international staging system for multiple myeloma : a report from International Myeloma Working Group. J Clin Oncol. 2015 ; 33 : 2863-9.
 
15) International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol. 2003 ; 121 : 749-57.
 
16) Palumbo A, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 ; 32 : 587-600.
 
P.305 掲載の参考文献
1) Thol F, et al. How I treat refractory and early relapse acute myeloid leukemia. Blood. 2015 ; 126 : 319-27.
 
2) Chevallier P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients : a GOELAMS study. Leukemia. 2011 ; 25 : 939-44.
PubMed
3) Yamauchi T, et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res. 2012 ; 32 : 5051-7.
PubMed
4) Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the National LymphoCare Study. J Clin Oncol. 2015 ; 33 : 2516-22.
PubMed
5) Majithia N, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016 ; 30 : 2208-13.
PubMed
6) Ong SY, et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era : analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplant. 2016 ; 51 : 933-7.
 
P.309 掲載の参考文献
1) Jerusalem G, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 2003 ; 14 : 123-30.
PubMed
2) Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011 ; 29 : 1844-54.
PubMed
P.310 掲載の参考文献
1) Tefferi A, et al. Eosinophilia : secondary, clonal and idiopathic. Br J Haematol. 2006 ; 133 : 468-92.
PubMed
2) Chikama R, et al. Nonepisodic angioedema associated with eosinophilia : report of 4 cases and review of 33 young female patients reported in Japan. Dermatology. 1998 ; 197 : 321-325.
PubMed
3) Kilon AD. How I treat hypereosinophilic syndromes. Blood. 2009 ; 114 : 3736-41.
 
4) Roufosse FE, et al. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007 ; 2 : 37.
PubMed
P.315 掲載の参考文献
1) IgG4関連疾患包括診断基準 2011. 日内会誌. 2012 ; 101 : 795-804.
 
2) 脇口宏, 他. EBウイルスと伝染性単核症, EBウイルス, EBウイルスとリンパ腫. In : 新村眞人, 山西弘一, 編. ヘルペスウイルス感染症. 臨床医薬研究協会 ; 1996. p.251-8.
 
3) 脇口宏, 感染症診断のピットフォール-EBウイルス感染症から学んだこと. 小児感染免疫. 2008 ; 20 ; 213-8.
 
4) Dunmire SK, et al. Infectious mononucleosis. Curr Top Microbiol Immunol. 2015 ; 390 : 211-40.
PubMed
5) 金兼弘和, 他. 慢性活動性EBウイルス感染症. モダンメディア. 2010 ; 56 : 93-9.
 
6) Duma G, et al. Kikuchi-Fujimoto Disease. Medicine. 2014 ; 93 : 372-82.
 

第3章 : 出血・凝固系疾患

P.330 掲載の参考文献
1) 藤村欣吾, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年度版. 臨床血液. 2012 ; 53 : 627-32.
 
2) 宮川義隆, 他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液. 2014 ; 55 : 934-47.
 
3) Kurata Y, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan : a population-based study and literature review. Int J Hematol. 2011 ; 93 : 329-35.
PubMed
4) Scully M, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 ; 158 : 323-35.
PubMed
5) 五十嵐隆, 他. 溶血性尿毒症症候群の診断・治療ガイドライン. http://www.jsn.or.jp/academicinfo/report/hus2013book.pdf
 
6) DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準暫定案. 血栓止血誌. 2014 ; 25 : 629-46.
 
7) 難病情報センター・血栓性血小板減少性紫斑病 (TTP) (指定難病). www.nanbyou.or.jp/entry/246
 
P.353 掲載の参考文献
1) 山崎雅英. 抗リン脂質抗体症候群の治療. 血栓止血誌. 2008 ; 19 : 333-5.
 
2) 母性内科学会. 抗リン脂質抗体症候群合併妊娠診療ガイドライン. http://www.boseinaika.jp/doc/event_160218.pdf
 
3) Chee YL, et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol. 2008 ; 140 : 496-504.
PubMed
4) 田中一郎, 他. 後天性血友病A 診療ガイドライン. 血栓止血誌. 2011 ; 22 : 295-322.
 
5) 世界血友病連盟. 血友病医療のガイドライン. 日本赤十字社 ; 2005. http://www.pfc.jrc.or.jp
 
6) インヒビターのない血友病患者に対する止血治療ガイドライン : 2013年度版. 血栓止血誌. 2013 ; 24 : 619-39.
 
7) インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年度版. 血栓止血誌. 2013 ; 24 : 640-58.
 

文献

P.365 掲載の参考文献
A) 日本血液学会, 編. 血液専門医テキスト. 第1版. 東京 : 南江堂 ; 2011.
 
B) 日本血液学会, 編. 血液専門医テキスト. 第2版. 東京 : 南江堂 ; 2015.
 
C) 日本血液学会. 造血器腫瘍診療ガイドライン 2013年版. http://www.jshem.or.jp/gui-hemali/table.html
 
D) 押味和夫, 他編. EBM血液疾患の治療 2008-2009. 東京 ; 中外医学社 ; 2007.
 
E) 金倉譲, 他編. EBM血液疾患の治療 2010-2011. 東京 ; 中外医学社 ; 2009.
 
F) 金倉譲, 他編. EBM血液疾患の治療 2013-2014. 東京 ; 中外医学社 ; 2012.
 
G) 金倉譲, 他編. EBM血液疾患の治療 2015-2016. 東京 ; 中外医学社 ; 2014.
 
H) 三輪史朗, 他. 血液細胞アトラス. 第5版. 東京 ; 文光堂 ; 2004.
 
I) 吉田彌太郎, 編. 血液疾患診療ハンドブック. 改訂2版. 大阪 ; 医薬ジャーナル社 ; 2009.
 
J) 神田善伸, 編. 臨床に直結する血液疾患診療のエビデンス. 東京 ; 文光堂 ; 2009.
 
K) Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. WHO ; 2008.
 
L) Arber DA, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 127 : 2391-405.
 
M) Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 ; 127 : 2375-90.
 
N) 直江知樹, 他. WHO血液腫瘍分類 WHO分類2008をうまく活用するために. 大阪 ; 医薬ジャーナル社 ; 2010.
 
O) 神田善伸. 造血細胞移植診療実践マニュアル. 東京 ; 南江堂 ; 2015.
 
P) NCCN Guidelines(R) (AML, ALL, CML, MDS, Hodgkin lymphoma, NHL, LPL, multiple myeloma). https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
 
Q) 日本造血細胞移植データセンター. 2014年度 日本における造血幹細胞移植の実績. http://www.jdchct.or.jp/data/slide/2014/
 
R) ESMO Guidelines (AML, ALL, Hodgkin lymphoma, FL, MCL, MM, MPN, MDS, PTCL, CLL, DLBCL). http://www.esmo.org/Guidelines
 

書評

最近チェックした商品履歴

Loading...